Alkoxycarbonate Ester Prodrugs of Preclinical Drug Candidate ELQ-300 for Prophylaxis and Treatment of Malaria-Reference-Cited by-同舟云学术

Alkoxycarbonate Ester Prodrugs of Preclinical Drug Candidate ELQ-300 for Prophylaxis and Treatment of Malaria

Published:2017-09-27 Issue:10 Volume:3 Page:728-735
ISSN:2373-8227
Container-title:ACS Infectious Diseases
language:en
Short-container-title:ACS Infect. Dis.

Author:

Frueh Lisa¹²^ORCID,Li Yuexin¹,Mather Michael W.³,Li Qigui⁴,Pou Sovitj²,Nilsen Aaron¹,Winter Rolf W.¹,Forquer Isaac P.¹,Pershing April M.³,Xie Lisa H.⁴,Smilkstein Martin J.¹,Caridha Diana⁴,Koop Dennis R.⁵,Campbell Robert F.⁴,Sciotti Richard J.⁴,Kreishman-Deitrick Mara⁴,Kelly Jane X.¹,Vesely Brian⁴,Vaidya Akhil B.³,Riscoe Michael K.¹

Affiliation:

1. Experimental Chemotherapy Laboratory, VA Medical Center (Mail code RD-33), 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States

2. Department of Molecular Microbiology and Immunology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, United States

3. Department of Microbiology and Immunology, Drexel University, 2900 W. Queen Lane, Philadelphia, Pennsylvania 19129, United States

4. Experimental Therapeutics Branch, Military Malaria Research Program (MMRP), Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, Maryland 20910, United States

5. Department of Physiology and Pharmacology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon 97239, United States

Funder

U.S. Department of Veterans Affairs

National Institute of Allergy and Infectious Diseases

U.S. Department of Defense

U.S. Army

Publisher

American Chemical Society (ACS)

Subject

Infectious Diseases

Link

https://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.7b00062

Reference39 articles.